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OBJECTIVE: The cost-effectiveness of heart failure (HF) disease
management depends on avoiding future high costs. Prospec-
tively identifying HF patients who are likely to incur high costs
would be beneﬁcial. METHODS: We used a 100% sample of
1,363,977 Medicare beneﬁciaries hospitalized with a primary
diagnosis of HF (ICD-9-CM codes 428.x, 402.x1, 404.x1,
404.x3) between 2001 and 2004. The earliest HF hospitalization
for each beneﬁciary was considered the index. We summed Medi-
care payments for rehospitalizations in the year following the
index hospitalization, adjusted costs to 2001 dollars, and created
a binary variable, with patients in the 4th quartile (>$16,500)
deﬁned as “high cost.” Comorbidities and risks were obtained
from the index claim and from inpatient claims in the prior year.
Logistic regression was used to predict high cost status in a 75%
random derivation sample; the model was validated in the
remaining 25%. We evaluated the calibration and discrimination
of the model in both samples and reﬁt the model on the entire
sample. RESULTS: Average Medicare payments in the year
following index hospitalization were $38,300 (SD $29,146)
among high cost patients and $4272 (SD $4857) among patients
in the lower 3 quartiles. Inpatient cost in the prior year was the
strongest predictor of inpatient cost in the subsequent year (OR
2.31, 95% CI: 2.27–2.35 for prior year inpatient costs >$16,500
vs. no inpatient costs in the prior year.) In both the derivation and
validation cohorts, 11% of patients in the lowest decile and 45%
of patients in the highest decile were high cost. The model was
well-calibrated. The c-statistic was 0.65 for both the derivation
and validation cohorts. CONCLUSION: There is limited ability
to predict high cost HF patients using claims data alone. Future
studies should assess the value of incorporating clinical variables.
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IMPACT OF ADOPTION OF NEW ANTIHYPERTENSIVE DRUGS
ONTHE HEALTH CARE UTILIZATION IN HYPERTENSIVE
PATIENTS
Ganguli A, Hong SH,Wingate L
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OBJECTIVE: This study aims to analyze the hypothesis that
utilization of newer medications is associated with decreased
health care utilization and increased quality of life in patients
with hypertension. METHODS: This is a retrospective follow up
study of patients identiﬁed as hypertensive (ICD-9-CM codes
401–405) and prescribed at least one antihypertensive medica-
tion during round one of 1999 MEPS database. Antihypertensive
drugs approved by FDA during the years 1996, 1997 and 1998
were deﬁned as ‘new antihypertensive drugs’. New drug adopters
(NDA) were those hypertensive patients who were prescribed
atleast one new antihypertensive medication. The total health
care expenditure and the non-prescription health care expendi-
ture were taken as markers for health care utilization and the
number of ER visits was a marker for quality of life of a patient.
RESULTS: Fourteen new antihypertensive drugs were approved
by FDA during the year 1996 (3), 1997 (7) and 1998 (4). A total
of 1149 (un-weighed) patients were identiﬁed as the study popu-
lation of which 63 (5.88%) patients were identiﬁed as NDA’s.
Females comprised 66.67% (42) in NDA’s and 49.82% (534) in
non-NDA’s. The New drug adopters were found to spend $637
& $675 more on total health care expenditure and on non-
prescriptions expenses respectively as compared to non-NDA’s.
Also NDA’s had 0.124 more ER visits as compared to non-
NDA’s. These results were statistically insigniﬁcant at 0.05 level
when adjusted for age, gender, income, race, ethnicity, number of
co-morbid conditions and insurance status. CONCLUSION: No
relation was found between the total health care utilization and
adoption of newer antihypertensive medications on aggregate
level. This signiﬁes the need to scrutinize the pharmacoeconomic
evaluation of each new drug before acceptance by physicians and
pharmacy managers.
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OBJECTIVES: Assessment of point of care devices (POCs) that
measure INR does not typically include the impact of measure-
ment error on clinical decision-making. This study determined
the effect of POC measurement error on warfarin dosing
decisions, and how this effect varies over the INR scale.
METHODS: For each patient, INR was simultaneously mea-
sured using two different POC devices and standard laboratory
techniques. Clinicians blinded to INR measurement technique
were asked to state a warfarin dosing decision for each INR
value. The difference between each POC-derived INR and the
laboratory standard measure were recorded for each patient, as
were differences in warfarin dosing decisions based on the POC
devices versus laboratory standard measures. RESULTS: A total
of 202 patients on warfarin therapy were enrolled. Overall, the
POC devices resulted in different warfarin dosing decisions com-
pared to the laboratory standard in 114 of 404 instances (28%,
95% CI: 24–33%). Discordant dosing decisions resulting from
POC and laboratory measures were most common when the
laboratory INR was between 1.5–1.99 (40/92, 43%, 95% CI:
33–55%) and 3–3.49 (15/36, 42%, 95% CI: 26–59%). Rela-
tively small amounts of measurement error from the POC devices
resulted in different warfarin dosing decisions between the labo-
ratory and POCs at speciﬁc intervals in the INR scale. For
example, overestimation of INR by the POC by 0.2–0.39 INR
units resulted in discordant warfarin dosing decisions in 44% of
instances when the laboratory INR was between 1.5–1.99.
CONCLUSIONS: Measurement error in POC devices leads to
different warfarin doses in a high proportion of cases. A rela-
tively small amount of measurement error can result in different
warfarin dosing decisions if it occurs at speciﬁc intervals on the
INR scale. Investigators and regulators should consider the
varying effect of measurement error along the INR scale and its
impact on clinical decision-making when evaluating POCs.
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OBJECTIVE: Estimating the cost-effectiveness of disease man-
agement programs requires a comprehensive assessment of per-
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